Amlitelimab ELISA Kit

Catalog No.

KDD58802

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD252 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Amlitelimab in the sample competitively binds to the pre-coated protein with biotin-labeled Amlitelimab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Amlitelimab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Amlitelimab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

125 - 8,000 ng/mL

Sensitivity

11.05 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	3891.0	1109.6	192.5	3915.3	1114.5	226.5
Standard deviation	314.8	100.2	32.8	273.7	111.6	36.5
CV (%)	8.1	9.0	17.0	7.0	10.0	16.1

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

KY-1005,KY1005,KY1005-2D10，KY-1005-2D10, CAS: 2378692-15-8

OX40/OX40L as a Therapeutic Target in Atopic Dermatitis: A Scoping Review., PMID:40331215

Safety and Efficacy of Anti-OX40 Therapies in Atopic Dermatitis: A Systematic Review and Meta-Analysis., PMID:40229131

Investigating Efficacy of Atopic Dermatitis Systemic Therapeutics After Discontinuation Part I: Biologics., PMID:40078859

Targeting the OX40-OX40L pathway: A new era in atopic dermatitis management by T-cell rebalancing., PMID:39978683

A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab., PMID:39565527

Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease., PMID:39544897

Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis., PMID:39522654

A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis., PMID:39064040

Emerging drugs for the treatment of atopic dermatitis: a focus on phase 2 and phase 3 trials., PMID:38662529

OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target., PMID:38236520

An overview of new and emerging antibody therapies for moderate-severe atopic dermatitis in adults., PMID:38054328

Safety and effectiveness of amlitelimab, a potential new treatment for atopic dermatitis: results of a clinical trial., PMID:37879745

Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial., PMID:37463508

OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab., PMID:36559247

OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005., PMID:35092305

Document Download

Amlitelimab ELISA Kit.pdf